SCHEMBL3749018

SCHEMBL3749018

O=C(c1ncco1)C1CCN(Cc2ccc3ccccc3c2O)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 10/20 0.62
KDM4E B2RXH2 4/20 0.52
ALDH1A1 P00352 3/20 0.52
MAPT P10636 3/20 0.52
KMT2A Q03164 2/20 0.52
GAA P10253 2/20 0.52
LMNA P02545 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.43
TP53 P04637 1/20 0.43
ALOX12 P18054 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ATM Q13315 1/20 0.42
CACNA1B Q00975 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3753424 0.89 FAAH (0.65) FAAHKMT2A
SCHEMBL3759855 0.81 FAAH (0.64) FAAHL3MBTL1
SCHEMBL3747423 0.81 FAAH (0.69) FAAHALDH1A1ATM
SCHEMBL3748295 0.81 FAAH (0.69) FAAHALDH1A1KMT2A
SCHEMBL3751195 0.80 FAAH (0.68) FAAH
SCHEMBL3755602 0.80 FAAH (0.61) FAAHKDM4EALDH1A1KMT2ATDP1
SCHEMBL3747521 0.80 FAAH (0.68) FAAHKDM4EALDH1A1KMT2ALMNA
SCHEMBL3748182 0.79 FAAH (0.66) FAAHKMT2A
SCHEMBL3759718 0.79 FAAH (0.58) FAAHL3MBTL1
SCHEMBL3747543 0.78 FAAH (0.60) FAAHKDM4EALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US claimed
EP-2023728-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE Janssen Pharmaceutica, N.V. (BE) 2009-02-18 EP claimed
WO-2007140005-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 WO claimed
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US disclosed
WO-2007140005-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase FAAH, FAAH2, APEH FAAH 1/4885KDM4E 815/4885ALDH1A1 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.